ASTX

Astex Pharmaceuticals

NASDAQ

Add Alert

ASTX

Astex Pharmaceuticals

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

M-invest

09/02/16 12:18 PM

Post #217

If down I will buy some .0030 area

ManicTrader Free

11/23/13 10:44 PM

Post #216

Re: #212: @TheFinalCD - Moreover, as recently as July 19, 2013, an

$ASTX was a great trade for us

surf1944

10/10/13 8:20 AM

Post #215

Re: #204: @surf1944 - 3:54AM Astex Pharma to be acquired by Otsuka

1:50AM Astex Pharma responds to claims by Sarissa Capital (ASTX) 8.49 : Co issues the following statement in response to claims made by Sarissa Capital:

"We are disappointed that Sarissa Capital continues to mislead Astex stockholders with information that is incomplete, taken out of context and does not provide full and accurate information to Astex stockholders.In a last-ditch attempt to unnecessarily delay and possibly derail the premium, all-cash transaction with Otsuka, earlier today Sarissa Capital issued a press release about a collaborators' compound, LEE011, a clinical-stage, potential cancer treatment that is being developed by Novartis. Consider these facts:

The Astex Board of Directors Considered LEE011 in its Deliberations. The Astex Board carefully considered the potential benefit and risks of LEE011 as it made its determination that the premium, $8.50 per share all-cash transaction with Otsuka was in the best interests of all Astex stockholders.
Astex has Repeatedly Discussed the Progress of LEE011. Astex publicly discussed LEE011 as recently as August 1, 2013 on the Company's second quarter earnings conference call, and provided an update on LEE011 in its investor corporate presentations.
Interested Parties Had Knowledge of LEE011 During Diligence. The Otsuka transaction was the culmination of a comprehensive process to maximize value for all Astex stockholders. As part of that process, 33 pharmaceutical companies worldwide were contacted to gauge their interest in exploring a potential strategic transaction with Astex. Each of the parties who conducted diligence had access to confidential information related to the Company's pipeline, including its partnered products such as LEE011.
LEE011 is Many Years from Approval. Despite Sarissa Capital's hype, LEE011 is still in Phase I/II clinical trials and Novartis has not informed Astex of any patients treated in Phase II trials, let alone in Phase III trials. While Novartis has recently made the decision to enter Phase III clinical trials with the experimental drug,
LEE011 is still many years away from potential FDA approval and market entry. Furthermore, while Astex has confidence in LEE011, as we have referenced historically, there is high risk associated with the development of any drug, in particular one that is still only in Phase I clinical trials. Novartis' estimated completion date of this phase III trial is November of 2016.
Sarissa Overstates the Potential, Long-Range Economic Impact LEE011 Might Have Upon Astex.
LEE011 has Minimal Impact on Astex' Valuation. Novartis has the exclusive right to develop and commercialize LEE011 with Astex having no right to co-develop or co-promote. Therefore, even if the clinical trials are successful, and market approval is eventually granted, the contribution to today's valuation is minimal.
...The Astex Board of Directors unanimously recommends that our fellow stockholders tender into Otsuka's $8.50 per share cash offer, which is initially scheduled to expire October 10, 2013..."

TheFinalCD PremiumMember

09/08/13 7:57 PM

Post #214

Re: #213: @ilpapa - Am I right in assuming any deal will

dam me I had 20k shares and sold under $8.50

GRRRRRRRRRRRRRRRRRRRRRRRRR

ilpapa

09/08/13 12:17 PM

Post #213

Re: #212: @TheFinalCD - Moreover, as recently as July 19, 2013, an

Am I right in assuming any deal will have to be approved by share holders?

TheFinalCD PremiumMember

09/06/13 7:28 AM

Post #212

Re: #211: @ECole - Updates during conf call.. Otsuka Pharmaceutical Company Limited's

Moreover, as recently as July 19, 2013, an analyst at Brean Capital, LLC set a target price of $13.00 per share, and an analyst at RBC Capital Markets set a target price of $9.00 per share on April 4, 2013. ASTX

ECole

09/06/13 5:46 AM

Post #211

Updates during conf call.. Otsuka Pharmaceutical Company Limited's agreement to acquire Astex Pharmaceuticals Incorporated for $8.50 per fully diluted share in cash for total consideration of approximately $886 million calculated using the Treasury Stock Method.

http://www.earningsimpact.com/Transcript/83446/ASTX/Astex-Pharmaceuticals%2c-Inc----Otsuka-Pharmaceutical-to-Acquire-Astex-Pharmaceuticals

southpawplayer23 Free

09/05/13 8:58 PM

Post #210

Re: #196: @TheFinalCD - CONGRAT$$$$$$$$$$$$$$$

Thanks my man!!! Still holding just in case another bid comes in on the weekend

north40000 PremiumMember

09/05/13 2:03 PM

Post #209

Re: #208: @RxJoshRx - 8.54 just posted. Not sure why we are

Mike King views on ASTX buy-out courtesy of dough:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91720435

.....the proposed $8.50 per share offer from Otsuka is wholly inadequate considering the valuable collection of assets Astex has assembled.....

RxJoshRx

09/05/13 1:05 PM

Post #208

8.54 just posted. Not sure why we are above the 8.50 price...any news/rumors out?

ManicTrader Free

09/05/13 12:39 PM

Post #207

Re: #206: @TheFinalCD - yeah no flippin there....

4,900% Gains! Sept 9 calls in Aug .01-.50 * Sept 6 calls in Aug 2,900% Gains! .10-3.00 Who doesn't like gains like this?? This chart caught me eye last year with lots of potential upside. Patience prevails once again. This is round 2 for me, 1st alert to followers at in January 2012 2.44-6.95 and then again at 7/2/2013 4.35-9.39

Free Breakout Newsletter http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88550626

TheFinalCD PremiumMember

09/05/13 12:30 PM

Post #206

Re: #205: @gixxer11 - Holy crap talk about a tight trading range

yeah no flippin there....

gixxer11

09/05/13 12:26 PM

Post #205

Re: #202: @TheFinalCD - geez I just left $2k on the table:-(

Holy crap talk about a tight trading range

surf1944

09/05/13 10:14 AM

Post #204

Re: #183: @surf1944 - 6:01AM Astex Pharma announces topline results of SGI-110

3:54AM Astex Pharma to be acquired by Otsuka Pharma for $8.50 per share in cash (ASTX) 8.27 : Otsuka Pharmaceutical and Astex Pharmaceuticals announce that their respective Boards of Directors have unanimously approved a transaction under which Otsuka will acquire all of the outstanding shares of Astex for $8.50 per share in cash representing a 48% premium to the average closing stock price for the prior 30 day period. The purchase price represents a fully diluted equity value of ~$886 mln, calculated using the treasury stock method

NewTrader17 Free

09/05/13 10:00 AM

Post #203

Re: #202: @TheFinalCD - geez I just left $2k on the table:-(

Bad time to buy ASTX? not going on vacation anymore :/ missed out on this one...Suggestions appreciated in advance :)

TheFinalCD PremiumMember

09/05/13 8:40 AM

Post #202

Re: #200: @$$$eeker - $ASTX I bought @$7.06 and sold @ $9.00

geez I just left $2k on the table frown

ASTX Sold Processing XWA01A320130905 10000 $8.46 $84,591.52 8:25:34 AM 9/5/2013 9/10/2013
ASTX Sold Processing XMB284520130905 2700 $8.45 $22,814.60 8:23:35 AM 9/5/2013 9/10/2013
ASTX Sold Processing XMB284520130905 4500 $8.45 $38,017.33 8:23:35 AM 9/5/2013 9/10/2013
ASTX Sold Processing XMB284520130905 2000 $8.45 $16,899.70 8:23:35 AM 9/5/2013 9/10/2013
ASTX Sold Processing XMB284520130905 800 $8.45 $6,759.88 8:23:35 AM 9/5/2013 9/10/2013

TheFinalCD PremiumMember

09/05/13 8:18 AM

Post #201

Re: #200: @$$$eeker - $ASTX I bought @$7.06 and sold @ $9.00

nice= http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91683329

$$$eeker

09/05/13 8:12 AM

Post #200

Re: #199: @TheFinalCD - too bad for TOP buyers

$ASTX I bought @$7.06 and sold @ $9.00

TheFinalCD PremiumMember

09/05/13 8:06 AM

Post #199

Re: #198: @$$$eeker - Yesterday's news stated a buyout price of $9.50/sh,

too bad for TOP buyers

$$$eeker

09/05/13 8:05 AM

Post #198

Re: #197: @TheFinalCD - $8.50 and it hit $9.39 yest

Yesterday's news stated a buyout price of $9.50/sh, that's why it hit $9.39.

TheFinalCD PremiumMember

09/05/13 7:59 AM

Post #197

Re: #189: @$$$eeker - $ASTX bought out for 9.50/sh

$8.50 and it hit $9.39 yest

TheFinalCD PremiumMember

09/05/13 7:54 AM

Post #196

Re: #192: @southpawplayer23 - Nothing is finalized yet... When we have a

CONGRAT$$$$$$$$$$$$$$$

north40000 PremiumMember

09/05/13 4:45 AM

Post #195

Re: #194: @faraifarai - Otsuka Holdings Says It Hasn’t Yet Decided to

Mind made up

http://www.reuters.com/article/2013/09/05/us-astex-offer-otsuka-idUSBRE98407Q20130905

faraifarai Free

09/04/13 11:40 PM

Post #194

Re: #193: @RxJoshRx - And we still have not heard anything from

Otsuka Holdings Says It Hasn’t Yet Decided to Buy Astex
By Alex Nussbaum & Marco Lui - Sep 4, 2013 7:00 PM MT

Otsuka Holdings Co. (4578), the maker of the mood-stabilizing drug Abilify, said it hasn’t yet decided to buy Astex Pharmaceuticals Inc. (ASTX), responding to a Nikkei report that it intends to pay 90 billion yen ($900 million) for the U.S. biotechnology company.
Otsuka isn’t the source of yesterday’s newspaper report, the company said today in a statement to the Tokyo Stock Exchange. It will make an announcement once a decision is made. Astex surged 24 percent to a nine-year high of $8.27 at the close in New York yesterday, valuing the Dublin, California-based company at $785 million.
Otsuka, which also makes Pocari Sweat drinks and Soyjoy nutrition bars, wants to buy Astex to increase its stable of cancer drugs, the Nikkei report said. With one leukemia drug on the market and other treatments under development, Astex may command a higher price or attract other bidders, said Gene Mack, a Brean Capital LLC analyst based in New York.
“If it’s for real, I think the offer is too low,” Mack said in a telephone interview. “Any oncology company would look at it as a target.”
Otsuka fell as much as 0.4 percent to 2,970 yen in Tokyo trading, and traded down 0.2 percent at 2,974 yen as of 9:56 a.m. The shares have advanced 22 percent this year, lagging behind the 35 percent increase of the benchmark Topix index.
Astex’s SGI-110, an experimental treatment for acute myeloid leukemia, had positive results in a mid-stage clinical trial, the company said in an Aug. 28 statement. It has one marketed product, Dacogen, a leukemia drug licensed for sale by Eisai Co. and a unit of Johnson & Johnson.
Timothy Enns, a spokesman for Astex, didn’t respond to an e-mail and telephone call seeking comment on the report.
Abilify is one of the world’s best-selling schizophrenia treatments. Otsuka has been searching for new products before 2015, when its patent on Abilify expires.

RxJoshRx

09/04/13 5:23 PM

Post #193

Re: #192: @southpawplayer23 - Nothing is finalized yet... When we have a

And we still have not heard anything from ASTX yet to confirm or deny the buyout.

ASTX could come out and say they don't except the offer and want a higher offer- could send the shares higher short term.

I bought Oct $9 calls late this afternoon at $0.30. Went with October instead of September since they were only $0.05 more and getting another full month.

southpawplayer23 Free

09/04/13 4:07 PM

Post #192

Re: #191: @faraifarai - I'm a shareholder from $4. Can someone explain

Nothing is finalized yet... When we have a deal the stock price will reflect what they bought us for. As far as cashing out. You can either cash out at market or wait for a proxy statement that will give you options from there... Ex. Cash and stock options going forward.. Your broker will assist you through the process if need be.

faraifarai Free

09/04/13 3:42 PM

Post #191

Re: #190: @~S.B.A.~ - buyout on the open market

I'm a shareholder from $4. Can someone explain how this buyout works? If it's $9.50 share, how long will it be traded? I guess in sum? How do i cash out? Why hasn't share price gone above $9, etc if those are the terms.

thanks

~S.B.A.~

09/04/13 1:20 PM

Post #190

Re: #186: @gixxer11 - News ?

buyout on the open market

$$$eeker

09/04/13 1:19 PM

Post #189

Re: #188: @gixxer11 - So cash value around $9 pps ?

$ASTX bought out for 9.50/sh

gixxer11

09/04/13 1:17 PM

Post #188

Re: #187: @$$$eeker - Otsuka To Buy U.S. Start-Up Astex Pharmaceuticals

So cash value around $9 pps ?

$$$eeker

09/04/13 1:11 PM

Post #187

Re: #186: @gixxer11 - News ?

Otsuka To Buy U.S. Start-Up Astex Pharmaceuticals
http://e.nikkei.com/e/fr/freetop.aspx

gixxer11

09/04/13 1:08 PM

Post #186

Re: #185: @~S.B.A.~ - weeeee 1 minute chart wwwwww

News ?

~S.B.A.~

09/04/13 1:07 PM

Post #185

Re: #184: @ManicTrader - Not really sure bro, lets look into that

weeeee 1 minute chart wwwwww

ManicTrader Free

08/28/13 12:04 PM

Post #184

Re: #182: @southpawplayer23 - Was this the data that was suppose to

Not really sure bro, lets look into that

surf1944

08/28/13 9:40 AM

Post #183

Re: #157: @surf1944 - Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data

6:01AM Astex Pharma announces topline results of SGI-110 AML Phase 2 study; as of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML (ASTX) 5.48 : Co announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course. As of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months. The primary endpoint is overall remission rate (Complete Remission or CR; Complete Remission with Incomplete hematologic recovery or CRi/CRp). There were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naive elderly AML for an overall complete remission rate of 17/67 or 25%.

southpawplayer23 Free

08/28/13 9:25 AM

Post #182

Re: #181: @ManicTrader - YES

Was this the data that was suppose to come out in December?

ManicTrader Free

08/28/13 9:18 AM

Post #181

Re: #179: @southpawplayer23 - You think we get to the high of year?

YES

ManicTrader Free

08/28/13 9:18 AM

Post #180

Re: #177: @TheFinalCD - ASTX lets ROLL!

$ASTX Breaking News! Up 20.5% Pre Mrkt

Astex Pharma announces topline results of SGI-110 AML Phase 2 study; as of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML (5.48 ) : Co announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course. As of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months. The primary endpoint is overall remission rate (Complete Remission or CR; Complete Remission with Incomplete hematologic recovery or CRi/CRp). There were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naive elderly AML for an overall complete remission rate of 17/67 or 25%.

Astex Pharma announces first data showing early combination treatment of HSP90 Inhibitor AT13387 With targeted agents delays emergence of resistance in preclinical models (5.75 ) : Co announces data demonstrating for the first time that early treatment with AT13387, a second generation, fully synthetic HSP90 inhibitor, in combination with targeted therapy delays the emergence of resistance.

In a preclinical model of mutant BRAF melanoma, animals were treated with vemurafenib alone or vemurafenib in combination with AT13387. After 2 to 4 months of continued treatment, tumor-bearing mice treated with vemurafenib alone showed the emergence of resistance and tumor regrowth while animals treated with the combination of vemurafenib and AT13387 did not show such regrowth. In addition, tumors that became resistant to vemurafenib alone were still sensitive to AT13387 treatment.

southpawplayer23 Free

08/28/13 9:15 AM

Post #179

You think we get to the high of year?

dshade

08/28/13 9:12 AM

Post #178

decent start alright

TheFinalCD PremiumMember

08/28/13 9:00 AM

Post #177

Re: #172: @ManicTrader - Good eyes FL, used to follow the sar

ASTX lets ROLL!

ASTX Bought Processing XCC1C6720130828 1000 $6.35 $6,357.00 8:42:33 AM 8/28/2013 9/3/2013
ASTX Bought Processing XIAEC7120130828 1900 $6.35 $12,065.00 8:27:36 AM 8/28/2013 9/3/2013
ASTX Bought Processing XIAEC7120130828 100 $6.35 $642.00 8:27:33 AM 8/28/2013 9/3/2013

southpawplayer23 Free

08/28/13 8:57 AM

Post #176

O how I love beautiful morning with our positive data. So many positive things in this company

I Know BS

08/23/13 5:50 PM

Post #175

Re: #174: @binks - Nice move today

It will run higher, much higher. Market taking a liking to this run

binks

08/23/13 1:46 PM

Post #174

Nice move today

Penny Roger$ Free

08/22/13 7:22 AM

Post #173

Re: #172: @ManicTrader - Good eyes FL, used to follow the sar

Yep, there are many ways to play this game.

ManicTrader Free

08/22/13 12:19 AM

Post #172

Re: #170: @Penny Roger$ - These little poka dot sar signals are often

Good eyes FL, used to follow the sar but found some other oscillators that work better for me. What ever works and u feel comfy with i always say! 8)

ManicTrader Free

08/22/13 12:02 AM

Post #171

Re: #168: @I Know BS - Good entry point. This stock is definitely able

$ASTX 5.50, I Put back on the buy me list yesterday. Loaded 5.10 after she retested and held her 50ma support 2nd time. I put alot of time in following this stock and has made me good money.

ManicTrader Member Level

Tuesday, November 20, 2012 1:07:37 PM
Re: None
Post # of 13074
$ASTX 2.44 Alert, 2.15 support here

Alerts like these 100% Free: http://trumpia.com/onlineSignup/ManicStockAlerts/ManicTraders

1 yr Fibonacci Retracement

6 Month Daily

Penny Roger$ Free

08/21/13 11:16 PM

Post #170

Re: #169: @ManicTrader - YEAH i know lmao, wanted to slap a

These little poka dot sar signals are often like mini trend lines and in this case can signal a nice run in the making with all these higher highs in place.

ManicTrader Free

08/21/13 11:00 PM

Post #169

Re: #166: @Penny Roger$ - ~ $ASTX ~ Daily Par Sar Buy Signal

YEAH i know lmao, wanted to slap a post on here last night but got busy! Rinse n repeat

I Know BS

08/21/13 10:24 PM

Post #168

Re: #167: @binks - I got in the other day with 2.5k

Good entry point. This stock is definitely able to explode and has proved consistently to have a history of success. I believe that all the trials will be successful especially SG-110. SG-110 is simply an amplified version of dacogen that the company has specifically stated in press releases and conference calls is eager to present data. Not to mention anyone knowing anything about the small cap biotech sector knows that stocks usually run into the upcoming data with or without success. There is a lot of money to be made here, enjoy the ride.

Older

Astex Pharmaceuticals (ASTX)

Followers	14	Posters	48
Posts (Today)	0	Posts (Total)	217
Created	07/16/07	Type	Free
Moderators

http://astx.com/

http://www.supergen.com/

http://finance.yahoo.com/q/ks?s=astx

http://www.secform4.com/insider-trading/919722.htm

SuperGen, Inc., a pharmaceutical company, engages in the discovery, acquisition, development, and commercialization of therapies to treat patients with cancer. It offers Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites. The company also involves in developing various therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase, and DNA methyltransferase. Its generic anti cancer products include Mitomycin and Paclitaxel for solid tumors. The company's formulation products include Mitozytrex; Partaject busulfan for neoplastic meningitis/bone marrow transplant in Phase I/II; Partaject Orathecin and Cremophor-free paclitaxel for solid tumors in pre clinical stage; and CZ 112 for solid tumors in Phase I. SuperGen's other product candidates include Avicine, a therapeutic vaccine in Phase II; and VEGF, an anti angiogenesis in pre clinical stage. It has collaborations with MGI PHARMA, Inc.; The Stehlin Foundation for Cancer Research; Warner-Lambert Company; Peregrine Pharmaceuticals; AVI BioPharma, Inc.; and University of Arizona. The company sells its products to clinics, hospitals, and hospital buying groups in the United States, as well as to drug distributors and wholesalers in the United States and Europe. SuperGen was founded in 1991 and is headquartered in Dublin, California.